https://pioneerinstitute.org/wp-content/uploads/drug_cost.png 512 1000 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2022-11-02 12:50:442022-11-02 12:54:47Is CHIA’s Drug Cost Data Reliable?
Earlier this year, the Center for Health Information and Analysis (CHIA) released its Annual Report on the Performance of the Massachusetts Health Care System for 2020. The Massachusetts Legislature relies on CHIA data when considering bills to regulate drug costs and prices. The advocacy group Health Care for All reported that CHIA data showed prescription drug spending grew by 7.7 percent in 2020, more than twice the benchmark - but the most reliable data on prescription drugs indicates that spending in 2020 was essentially flat.
https://pioneerinstitute.org/wp-content/uploads/Untitled-design-2022-09-16T095137.929.png 512 1000 Gauri Binoy https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Gauri Binoy2022-09-16 09:49:442022-09-16 09:52:05Is this PBM tactic blocking healthcare access?
Utilization Management (UM) was originally a strategy designed to improve the safety, quality, and cost-effectiveness of physician prescribing. However, UM has grown exponentially over the last decade, becoming more a tactic for Pharmacy Benefit Managers (PBMs) to manage costs to benefit their bottom line.
https://pioneerinstitute.org/wp-content/uploads/Copy-of-11.-Employees-of-the-Public-Sector-5.png 512 1024 Gauri Binoy https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Gauri Binoy2022-08-08 15:26:072022-08-08 15:36:37The Realities Behind US Healthcare Spending
Healthcare policy is an all-encompassing term. It plays a role in every individual’s life; how it is curated, developed, and maintained has a significant long-term impact on the quality of life of any given community. It is critical that policymakers consistently adapt and amend healthcare policies in the ever-changing global pricing and affordability environment while providing funding support for optimal quality of care.
https://pioneerinstitute.org/wp-content/uploads/Copy-of-11.-Employees-of-the-Public-Sector-4.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2022-08-08 10:31:192022-08-08 10:36:28Cures for Patients, Not Health Plan Profits, Make Drugs Valuable
To the astonishment of many observers, the Institute for Clinical and Economic Review (ICER) recently concluded that a $2.1 million gene therapy for a life-threatening blood disorder called beta thalassemia, is priced cost-effectively. The surprise was especially pleasant, given that ICER’s methodology had, in the past, displayed bias against rare disease treatments and undervalued the lives of people living with disabilities.